Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell EK, Raje N, Cook D, Yee AJ, Logan E, Avigan DE, Jakubowiak A, Shaw K, Daley H, Nikiforow S, Griffin F, Cornwell C, Shen A, Heery C, Maus MV. Frigault MJ, et al. Among authors: maus mv. Blood Adv. 2023 Mar 14;7(5):768-777. doi: 10.1182/bloodadvances.2022007210. Blood Adv. 2023. PMID: 35468618 Free PMC article. Clinical Trial.
Chimeric antigen receptor-modified T cells strike back.
Frigault MJ, Maus MV. Frigault MJ, et al. Among authors: maus mv. Int Immunol. 2016 Jul;28(7):355-63. doi: 10.1093/intimm/dxw018. Epub 2016 Mar 28. Int Immunol. 2016. PMID: 27021308 Free PMC article. Review.
CARs in the Lead Against Multiple Myeloma.
Ormhøj M, Bedoya F, Frigault MJ, Maus MV. Ormhøj M, et al. Among authors: maus mv. Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2. Curr Hematol Malig Rep. 2017. PMID: 28233151 Free PMC article. Review.
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV. Scarfò I, et al. Among authors: maus mv. Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8. Blood. 2018. PMID: 30089630 Free PMC article.
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Boyiadzis MM, et al. Among authors: maus mv. J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. J Immunother Cancer. 2018. PMID: 30514386 Free PMC article. Review.
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Karschnia P, et al. Among authors: maus mv. Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26. Blood. 2019. PMID: 30808634 Free article.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. Among authors: maus mv. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
CAR-Based Approaches to Cutaneous T-Cell Lymphoma.
Scarfò I, Frigault MJ, Maus MV. Scarfò I, et al. Among authors: maus mv. Front Oncol. 2019 Apr 16;9:259. doi: 10.3389/fonc.2019.00259. eCollection 2019. Front Oncol. 2019. PMID: 31058076 Free PMC article. Review.
189 results